Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Among authors: ohtake t. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Prognostic Relevance of Tn Expression in Breast Cancer.
Tsuchiya A, Kanno M, Kawaguchi T, Endo Y, Zhang GJ, Ohtake T, Kimijima I I. Tsuchiya A, et al. Among authors: ohtake t. Breast Cancer. 1999 Jul 25;6(3):175-180. doi: 10.1007/BF02967164. Breast Cancer. 1999. PMID: 11091712
Evaluation of a novel medical device for pegfilgrastim administration.
Aruga T, Doihara H, Yanagita Y, Ishida T, Yamashita T, Uehara K, Taira T, Tsurutani J, Takeshita T, Tsuyuki S, Kaneko K, Ohtake T, Yamaguchi Y, Hara Y, Saji S. Aruga T, et al. Among authors: ohtake t. Cancer Sci. 2022 May;113(5):1763-1770. doi: 10.1111/cas.15335. Epub 2022 Mar 29. Cancer Sci. 2022. PMID: 35293085 Free PMC article.
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y. Kurebayashi J, et al. Among authors: ohtake t. Breast Cancer. 2021 May;28(3):684-697. doi: 10.1007/s12282-020-01205-w. Epub 2021 Feb 27. Breast Cancer. 2021. PMID: 33638810 Free PMC article. Clinical Trial.
427 results